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Abstract
A Ru-diimine wire, [(4,4’,5,5’-tetramethylbipyridine)2Ru(F9bp)]2+ (tmRu-F9bp, where F9bp is 4-
methyl-4’-methylperfluorobiphenylbipyridine), binds tightly to the oxidase domain of inducible
nitric oxide synthase (iNOSoxy). The binding of tmRu-F9bp is independent of tetrahydrobiopterin,
arginine, and imidazole, indicating that the wire resides on the surface of the enzyme, distant from
the active-site heme. Photoreduction of an imidazole-bound active-site heme iron in the enzyme-
wire conjugate (kET = 2(1) × 107 s-1) is fully seven orders of magnitude faster than the in vivo process.
Introduction
Nitric oxide synthase (NOS) is a heme monooxygenase that catalyzes the five-electron
oxidation of L-arginine and O2 to citrulline and nitric oxide (NO). NOS effects this
transformation in two turnovers, producing NG-hydroxy-L-arginine (NHA) as an enzyme-
bound intermediate, requiring three electrons from its reductase domain. Each turnover is
expected to proceed through a mechanism similar to that of cytochrome P450 (although the
two turnovers may utilize a different species for substrate oxidation), central to which are two
slow electron transfer (ET) events [1-6]. The first ET event reduces the resting, substrate-bound
heme to the ferrous state, which then binds oxygen to create the last observable intermediate
(ferric-superoxo) [4,7]. It is thought that the second ET event, where the electron is supplied
by the cofactor tetrahydrobiopterin (BH4), produces one or more high-valent heme species,
with substrate oxidation possibly occurring from a ferryl-porphyrin+• intermediate (Compound
I) [4,8]. The sluggishness of the second ET step, however, has so far prevented the
characterization of high-valent intermediates in the catalytic cycle in solution [3,4,9].
Cryoreduction of the heme domain of ferric-superoxo endothelial NOS at 77 K leads to the
formation of a ferric-peroxo species [3]. Annealing at 165 K results in conversion to the product
state without the appearance of intermediates. These data suggest that O-O bond cleavage is
slower than reaction with substrate.
By employing laser-induced ET to reduce the active-site heme very rapidly, it should be
possible to observe high-valent intermediates that follow in the catalytic cycle. Toward this
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end, we and others have developed photoactive electron tunneling wires to deliver electrons
and holes to and from the deeply buried heme active sites in P450cam [10-12] and NOS
[13-16]. Importantly, one of the NOS wires, tmRu-F9bp (Chart 1), can potentially probe the
catalytic cycle, since it binds tightly and specifically to the oxidase domain of the inducible
form of the enzyme (iNOSoxy) in a region that is distant from the active site [17]. Here we
demonstrate that an imidazole-ligated heme in tmRu-F9bp:iNOSoxy can be photoreduced
several million times faster (kET = 2(1) × 107 s-1) than the physiological ET reaction.
Materials and Methods
General
The tmRu-F9bp complex was synthesized as described previously [11,18,19].
Tetramethylphenylenediamine (TMPD) was obtained from Aldrich and vacuum-sublimed
before use. BH4 (Aldrich) was stored under argon at -20 °C. All other chemicals were used as
received from Sigma, JT Baker, Fischer, EM Sciences, and Mallinckrodt. UV-visible
absorption spectra were acquired on an Agilent 8453 UV spectrometer. Gel electrophoresis
was run on a Phast System (Pharmacia) with 8-25 percent gradient precast agarose gels and
SDS buffer strips. Samples were loaded in 4x SDS buffer and stained with Coomassie blue.
Samples were run against Precision Plus All-Blue standards (BioRad).
iNOSoxy expression and purification
The heme domain of iNOS with a C-terminal His6 tag was overexpressed in E. coli and purified
as described previously [20] with several exceptions. Briefly, expression cells were subjected
to two rounds of chemical lysis by pelleting and resuspension in 40 mL of B-PER lysis buffer
(protein extraction reagent B, Pierce). The lysis buffer included a cocktail of protease inhibitors
(10 μg/mL benzamidine, 5 μg/mL leupeptin, 1 μg/mL each pepstatin, antipain, and
chymostatin, and ~500 μM Pefabloc (Roche)) as well as 100 μg/mL DNase, 100 μg/mL RNase,
~500 μg/mL lysozyme, and 20 mM imidazole per liter of cells. The suspension was centrifuged
and the supernatant was loaded directly onto a His6 immobilized metalion affinity
chromatography column (5 mL Ni2+:HisTrap, Amersham). Once the protein was completely
loaded, it was washed with 20 column volumes of 20 mM imidazole in 50 mM NaPi/300 mM
NaCl/pH 8. The protein was eluted with 150 mM imidazole and concentrated to ~3 mL in an
Amicon Ultra centrifugation device (10,000 MWCO, Millipore). The concentrated sample was
then further purified over a size-exclusion column, as described previously [20]. The anion
exchange column was omitted when ≥95 percent purity was confirmed by UV-visible
spectroscopy and gel electrophoresis. The purified protein was concentrated to ~200 μM,
divided into 100 μL aliquots, and stored in 50 percent glycerol at -80 °C.
Sample preparation
Small aliquots of iNOSoxy were thawed and exchanged into phosphate buffer (50 mM KPi,
50 mM KCl, pH 7.4) using a PD-10 desalting column (BioRad) immediately before use. The
position of the heme Soret maximum (422 nm) confirmed the presence of low-spin, water-
bound heme [17,20]. The heme protein concentration was determined using ε422 = 75
mM-1cm-1 per unit heme [17]. For the inhibitor-bound samples, imidazole (400-500 μM) was
added, and binding was confirmed by a Soret shift to 428 nm [17,20]. For substrate-bound,
pterin-free samples, 1 mM arginine was added to dilute (~2-20 μM) iNOSoxy and allowed to
incubate at 4 °C for approximately 30 min. In the absence of pterin (BH4), only partial
conversion to a high-spin heme (λmax = 398 nm [20,21]) was observed. For substrate- and
pterin-bound samples, fresh BH4 solutions were prepared daily. Phosphate buffer was
thoroughly deoxygenated by bubbling with argon for ≥10 min. Solid BH4 was added to the
degassed buffer under a counter-flow of argon. Dilute iNOSoxy (~2-20 μM) was deoxygenated
by at least 30 evacuation-Ar backfill cycles, taking care to avoid bubbling of the solution.
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Aliquots of concentrated, deoxygenated pterin and arginine stocks were then added to the
protein solution, giving final concentrations of 100 μM BH4 and 1 mM arginine. The solution
was incubated for 2 h at 4 °C; binding of BH4 and arginine was confirmed by a Soret shift to
396 nm [22,23].
For quenching experiments, 1 M ascorbate stock solutions were prepared daily by dissolving
ascorbate in thoroughly deoxygenated 1 M KOH. Ascorbate (1 M) and solid TMPD were added
to deoxygenated protein solutions under a counter-flow of argon.
Transient spectroscopy
Luminescence decay and transient absorption measurements were made as described
previously [24-26]. The ~8 ns, 480 nm excitation pulses were produced by a Nd:YAG pumped
optical parametric oscillator. Data were collected at 1×109 samples s-1 using a LeCroy digital
oscilloscope. Transient absorbance data were converted from intensity to absorbance using the
following expression (Eq. 1):
(1)
where I is the intensity of light transmitted through the sample excitation volume, and I0 is the
average transmitted light intensity during the 200 ns prior to the laser shot. Luminescence decay
curves and transient absorbance traces were fit to one, two, or three exponentials using a
nonlinear least-squares algorithm (Eq. 2, Igor Pro):
(2)
Each experiment was repeated at least three times unless indicated otherwise.
Determination of RuI→FeIII ET rate constants
At a given time after excitation, the absorbance observed at a given wavelength (λ) between
400 and 450 nm is (Eq. 3):
(3)
Since ascorbate, TMPD, and TMPD+• do not absorb strongly in this region (under the
conditions of these experiments, Figure S2), the contributions of these species were neglected.
Owing to substantial populations of unbound Ru-complex, the absorbance changes at these
wavelengths due to depopulation of RuII and formation of *RuII are large compared to those
for FeII formation because [*RuII]≫[FeII]. Moreover, the presence of both free and iNOSoxy-
bound wire complicates the transient absorbance kinetics. In fitting these data, we were unable
to identify a phase that was distinct from those corresponding to *RuII decay in bound and free
wires, and that reliably could be attributed to intraprotein ET from RuI to FeIII (kET).
In order to characterize the RuI to FeIII ET kinetics, we developed a procedure to remove the
*RuII contribution from the transient absorbance kinetics. The isosbestic point for low-spin,
imidazole-bound FeIII iNOSoxy and the product FeII species occurs at 438 nm. In each
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experiment, therefore, transient absorbance of the Im-iNOSoxy/wire/quencher system at 438
nm reflects the *RuII bleach and recovery, but contains no contribution from iNOSoxy. Using
an experimentally validated *RuII-RuII difference spectrum, we determined scaling factors by
which we could multiply the 438 nm transient signals to produce estimates of the *RuII
contributions to the observed kinetics at several other wavelengths ([*RuII-RuII]: Δε452/
Δε438 = 1.12, Δε425/ Δε438 = 0.66). The calculated *RuII signals were subtracted from the
observed transient kinetics to produce signals corresponding to the time dependence of [FeII].
Transient RuI absorbance was neglected because its Δε values are <10 percent of those for
[FeII-FeIII] (Figure S5). The resulting corrected traces were then fit to single exponential
functions according to Eq. 2.
Results and Discussion
Binding of tmRu-F9bp to iNOSoxy
We have previously shown that tmRu-F9bp (Chart 1) binds to iNOSoxy independently of
substrate and BH4 with a dissociation constant of ~1 μM [17]. Remarkably, this wire binds at
a site distant from the active-site channel, as demonstrated by the finding that a known channel-
binding wire does not displace tmRu-F9bp from the enzyme [17]. While the precise binding
site has not been definitively established, Förster energy transfer measurements indicate that
it may be in the hydrophobic pocket thought to be the docking site for the iNOS reductase
domain [17,27]. Experiments with Ru(bpy)32+ show that the photosensitizer alone does not
bind to the enzyme (Figure S1), suggesting that the perfluorobiphenyl unit is largely responsible
for the strong association of the wire with a hydrophobic iNOSoxy surface region.
Quenching of the bound Ru-wire
In previous work, we described Ru-diimine wires that reduce the heme of cytochrome P450
directly upon photoexcitation [11]. In these experiments the wire termini ligated the iron center,
providing an efficient through-bond coupling pathway between the sensitizer and the heme. In
contrast, the Ru-wire described here does not directly photoreduce the heme, so we employed
a flash/quench method with exogenous reductants to produce FeII [28]. In this experiment, a
quencher (Q) reduces the photoexcited sensitizer to create a strongly reducing species (RuI in
Scheme 1). In the absence of other electron acceptors, the lifetime of RuI is dependent on the
rate of recombination with the oxidized quencher (kr in Scheme 1). Because Q+ and RuI are
present at low and equal concentrations, recombination is slow (ms timescale) and heme
reduction competes effectively.
Owing to its high solubility in water and lack of spectral interference with heme Soret changes,
ascorbate (Asc) is an attractive choice as a quencher for this system. Even at high concentrations
(10 mM), however, Asc quenching produces only small yields of FeII (Figures 1 and 2). TMPD
(Figure S3) is a better quencher than Asc, but has limited solubility in water [29, 30]. Further,
TMPD autoxidizes to create a soluble bright blue cation radical in aqueous media [31]. Under
conditions necessary for efficient excited-state quenching, the production of the radical rapidly
turns the solution dark blue, obscuring small transient changes in the heme spectrum
(Supporting Information).
These problems were overcome by employing both quenchers [32,33]. In a sample containing
10 mM Asc with saturated TMPD, the superior quenching capability of TMPD can be exploited
(Figure 1, red dotted trace) while Asc serves to keep the TMPD reduced. With Asc present,
TMPD+• does not accumulate, even after 60 min of photoexcitation in the presence of tmRu-
F9bp.
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Rapid production of reduced iNOSoxy
Single wavelength transient absorbance measurements with imidazole-bound iNOSoxy in the
presence of one equivalent of tmRu-F9bp, 10 mM Asc, and saturated TMPD reveal that
photochemically generated RuI disappears with concomitant formation of a new Fe species
within 50 ns of excitation at 480 nm (Figure 3). A difference spectrum constructed from the
single-wavelength data at 2 μs (Figure 4) shows the bleach of the Im-FeIII Soret absorption at
428 nm and increased absorbance to the red with a difference-spectrum maximum at 445 nm.
The rate of decay of RuI and reappearance of RuII is approximately equal to the rate of changes
in the Soret region. Given that RuII is reformed, the most likely explanation for spectral changes
between 400 and 450 nm is RuI to FeIII ET, which produces a new FeII heme species. Control
experiments with Ru(bpy)32+ indicate that the tmRu-F9bp perfluorobiphenyl moiety is required
for heme reduction. In the presence of Ru(bpy)32+ and quenchers, transient absorbance traces
show only the production of RuI (Figure S4).
In order to estimate the specific rate of FeII formation, *RuII contributions were subtracted
from the transient absorbance data as described in Materials and Methods (representative
single-wavelength traces are shown in Figure 5). The traces (a minimum of four wavelengths
from each of four different experiments completed on different days) were fit to a single
exponential function: kET = 2(1)×107 s-1.
This is a remarkably rapid reduction given the estimated Ru-heme distance of 20.2 Å [17] and
the absence of a through-bond pathway to the heme. Given its slim profile, hydrophobicity,
and potential to π-stack with aromatic residues, the perfluorobiphenyl moiety of tmRu-F9bp
may intercalate into the protein interior, leaving open the possibility of a through-wire hopping
mechanism [13].
Identity of the reduced species
In order to determine the nature of the product of electron transfer to the heme, the six-
coordinate FeIII-Im species was reduced under equilibrium conditions for comparison with the
transient data. Reaction of FeIII-Im with sodium dithionite in a glove box under an inert
atmosphere, followed by removal of excess dithionite on a size-exclusion (PD-10) column
equilibrated with 10 mM imidazole, produced a species with the absorption spectrum shown
in Figure 6.
Reduction of NOS has been extensively studied [9,23,34-37]. Six-coordinate ferrous-NO and
-CO species have been characterized by several investigators [23,36,37]; and, in the absence
of arginine and BH4, it has been shown that these six-coordinate species are unstable. Addition
of CO (or NO) to five-coordinate FeII causes a red-shift in the Soret band to 444 nm (or 440
nm) [23]. The 444 nm band blue-shifts over time to 421 nm, which suggests that a species
analogous to the inactive P420 form of cytochrome P450 is produced. It has been proposed
that the axial thiolate is not bound to the heme iron in the 421 nm species [23,37].
The blue-shift of the iNOSoxy Soret peak upon dithionite reduction (Figure 6, inset)
demonstrates that the red-shifted transient FeII species produced by photochemical heme
reduction likely has different axial coordination. The steady-state FeII absorption spectrum is
in good agreement with that reported for Drosphila melanogaster DHR51, a heme protein
believed to possess axial Cys and His ligands [38]. Similar spectra have been reported for
FeII forms of mutant cytochrome c and myoglobin engineered to have axial Cys and His ligands
[39,40]. In each of these FeII proteins, the Soret maximum is slightly blue-shifted relative to
its position in the FeIII form, indicating the presence of a low-spin FeII heme in which imidazole
remains bound but the thiolate ligand has been displaced. Further, five-coordinate ferrous
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iNOSoxy has been generated, showing a blue-shift of the Soret from the ferric species similar
to the spectrum in Figure 6 [23].
In contrast, the red-shifted Soret band found for photochemically reduced iNOS is analogous
to that resulting from cryoreduction of ferric cytochrome P450. Irradiation of six-coordinate
low-spin FeIII P450 in a frozen matrix produces a low-spin, presumably six-coordinate FeII
product [41]. Annealing at higher temperatures leads to the high-spin FeII product that is
observed under equilibrium conditions. We suggest that the transient FeII iNOS species formed
by photochemical reduction contains a low-spin FeII heme with axial Cys and imidazole
ligands. In our experiment, this species is likely reoxidized by TMPD+• before loss of axial
ligation, which would generate the species observed under equilibrium conditions.
Concluding Remarks
We have developed a system in which the heme of inducible nitric oxide synthase can be
photoreduced rapidly without interfering with substrate/cofactor binding. Employing flash-
quench experiments with a surface-binding Ru-diimine wire in combination with reductive
quenchers, we observed ET to the imidazole-bound heme of iNOSoxy fully seven orders of
magnitude faster than the natural reduction. This finding represents an important step toward
our goal of identifying reactive intermediates in the catalytic cycles of heme monooxygenases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
tmRu-F9bp  
[(4,4’,5,5’-tetramethylbipyridine)2Ru(F9bp)]2+
F9bp  
(4-methyl-4’-methylperfluorobiphenylbipyridine)
NO  
nitric oxide
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NOS  
nitric oxide synthase
iNOSoxy  
isolated oxygenase domain of murine inducible NOS
NHA  
NG-hydroxy-L-arginine
ET  
electron transfer
BH4 / pterin  
tetrahydrobiopterin
TMPD  
tetramethylphenylenediamine
Asc  
ascorbate
Q  
quencher
B-PER  
protein extraction reagent B (Pierce)
Pi  
phosphate, PO42-
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Figure 1.
Luminescence decay of 6.2 μM tmRu-F9bp bound to equimolar Im-iNOSoxy in the absence
of quenchers (black line) and in the presence of 10 mM Asc (blue dashes) or 10 mM Asc and
saturated TMPD (red dots). λex = 480 nm and λobs = 660 nm.
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Figure 2.
Transient absorbance of 1:1 mixtures of tmRu-F9bp and Im-iNOSoxy (6.2 μM) in the presence
of 10 mM Asc with (darker traces) and without (lighter traces) saturated TMPD. λex = 480 nm.
a) λobs = 418 nm. b) λobs = 445 nm. The addition of TMPD increases the yield of reduced heme.
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Figure 3.
Transient absorbance of quenched Im-iNOSoxy bound to 1 equivalent of tmRu-F9bp (11 μM
with 10 mM Asc and saturated TMPD). λex = 480 nm.
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Figure 4.
Transient absorbance of a 1:1 mixture of Im-iNOSoxy and tmRu-F9bp (22 μM with 10 mM
Asc and saturated TMPD) showing a characteristic Fe(III/II) difference spectrum. Individual
points were taken from single wavelength transient absorbance traces at 2 μs after excitation
at 480 nm.
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Figure 5.
Transient absorbance of Im-iNOSoxy bound to 1 equivalent of tmRu-F9bp (11 μM with 10
mM Asc and saturated TMPD) corrected for absorbance due to *RuII : kET = 2(1)×107 s-1;
λex = 480 nm.
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Figure 6.
Steady-state spectra of ferric-imidazole (red solid line) and the reduced species (green dashed
line). Inset: The difference spectrum generated upon reduction (red dotted line).
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Scheme 1.
Representation of the reversible flash/quench experiment employed in this work. For
simplicity, TMPD and ascorbate are represented together as Q. In a successful flash/quench
experiment, quenching must compete with intrinsic relaxation (k0) and energy transfer (ken)
for depletion of the RuII excited state (kQ[Q] ≥ k0 + k en); and electron transfer (kET) must be
faster than recombination between oxidized quencher and reduced sensitizer (t½ = 1/
kr[RuI]0).
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Chart 1.
tmRu-F9bp.
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